Clinical efficacy of laninamivir and peramivir in patients with seasonal influenza: a randomized clinical trial

Infectious Diseases

Volumn 49, Issue 5, 2017, Pages 417-419

  Yoshino, Yusuke ^a   Seo, Kazunori ^a   Koga, Ichiro ^a   Kitazawa, Takatoshi ^a   Ota, Yasuo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; ZANAMIVIR;

ANTIVIRAL THERAPY; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; HUMAN; LETTER; MEDICATION COMPLIANCE; MULTIPLE DRUG DOSE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAPID TEST; SEASONAL INFLUENZA; SINGLE DRUG DOSE; ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEMALE; INFLUENZA; JAPAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; CYCLOPENTANES; FEMALE; GUANIDINES; HUMANS; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; OSELTAMIVIR; TREATMENT OUTCOME; ZANAMIVIR;

EID: 84992017508     PISSN: 23744235     EISSN: None     Source Type: Journal    
DOI: 10.1080/23744235.2016.1242773     Document Type: Letter

References (10)

1. Hama R., The mechanisms of delayed onset type adverse reactions to oseltamivir. Infect Dis. 2016;48:651–660.
2. Jefferson T., The neuraminidase inhibitors evidence of harms–in context. Infect Dis. 2016;48:661–662.
3. Qiu S, Shen Y, Pan H, et al. Effectiveness and safety of oseltamivir for treating influenza:an updated meta-analysis of clinical trials. Infect Dis. 2015;47:808–819.
4. Hikita T, Hikita H, Hikita F, et al. Clinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patients. Int J Pediatr. 2012;2012:834181
5. Shobugawa Y, Saito R, Sato I, et al. Clinical effectiveness of neuraminidase inhibitors–oseltamivir, zanamivir, laninamivir, and peramivir–for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection:an observational study in the 2010-2011 influenza season in Japan. J Infect Chemother. 2012;18:858–864.
6. Yoshino Y, Seo K, Koga I, et al. Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan. Clin Respir J. 2015;9:228–232.
7. Sugaya N, Ohashi Y., Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010;54:2575–2582.
8. Takemoto Y, Asai T, Ikezoe I, et al. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012–2013. Chemotherapy. 2013;59:373–378.
9. Koseki N, Kaiho M, Kikuta H, et al. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011–2012 season. Influenza Other Respir Viruses. 2014;8:151–158.
10. Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55:5267–5276.